PDS Biotechnology Corp (PDSB)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $107.07M
Last updated: Nov 17, 2026 at 11:05 AM ET
PDS Biotechnology Corp (PDSB) Earnings: Report Dates and Results
PDS Biotechnology (PDSB) is expected to report earnings on Mar 29, 2027. In the quarter ended Sep 30, 2026, PDS Biotechnology reported EPS of -$0.11, below the -$0.09 estimate. It beat the EPS estimate in 6 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
PDSB has an expected report date of Mar 29, 2027.
PDSB Earnings Call
The latest PDSB earnings call transcript on file is labeled 2026Q1.
Read the 2026Q1 transcriptEarnings History
Of the 38 quarters below that had an estimate, PDSB beat 22 and missed 16. The widest gap in the table came in the quarter ended Sep 30, 2018, when EPS landed 748.15% below the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported |
|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.11 | -$0.09 | -$0.11 - -$0.07 | -22.22% | Miss | N/A | 2 | 1 up, 0 down | Nov 13, 2026 |
| Jun 30, 2026 | -$0.18 | -$0.13 | -$0.14 - -$0.12 | -38.46% | Miss | N/A | 3 | 0 up, 0 down | Aug 13, 2026 |
| Mar 31, 2026 | -$0.13 | -$0.14 | -$0.15 - -$0.13 | +7.14% | Beat | N/A | 2 | 0 up, 0 down | May 13, 2026 |
| Dec 31, 2025 | -$0.14 | -$0.18 | N/A | +20.77% | Beat | N/A | 1 | 1 up, 0 down | Mar 30, 2026 |
| Sep 30, 2025 | -$0.19 | -$0.20 | N/A | +5.00% | Beat | N/A | 2 | 3 up, 0 down | Nov 13, 2025 |
| Jun 30, 2025 | -$0.21 | -$0.23 | -$0.25 - -$0.22 | +8.70% | Beat | N/A | 3 | 2 up, 1 down | Aug 13, 2025 |
| Mar 31, 2025 | -$0.21 | -$0.25 | -$0.31 - -$0.19 | +16.00% | Beat | N/A | 3 | 2 up, 0 down | May 14, 2025 |
| Dec 31, 2024 | -$0.21 | -$0.28 | -$0.29 - -$0.25 | +23.64% | Beat | N/A | 4 | 2 up, 1 down | Mar 27, 2025 |
| Sep 30, 2024 | -$0.29 | -$0.28 | -$0.33 - -$0.26 | -3.57% | Miss | N/A | 5 | 2 up, 0 down | Nov 14, 2024 |
| Jun 30, 2024 | -$0.23 | -$0.33 | -$0.40 - -$0.29 | +30.30% | Beat | N/A | 5 | 1 up, 0 down | Aug 13, 2024 |
| Mar 31, 2024 | -$0.30 | -$0.37 | -$0.45 - -$0.28 | +18.92% | Beat | N/A | 6 | 0 up, 0 down | May 15, 2024 |
| Dec 31, 2023 | -$0.35 | -$0.42 | -$0.60 - -$0.37 | +16.67% | Beat | N/A | 7 | 0 up, 0 down | Mar 27, 2024 |
| Sep 30, 2023 | -$0.35 | -$0.47 | -$0.50 - -$0.32 | +25.53% | Beat | N/A | 7 | 0 up, 0 down | Nov 14, 2023 |
| Jun 30, 2023 | -$0.37 | -$0.34 | -$0.39 - -$0.29 | -8.82% | Miss | N/A | 7 | 0 up, 0 down | Aug 14, 2023 |
| Mar 31, 2023 | -$0.32 | -$0.30 | -$0.36 - -$0.25 | -6.67% | Miss | N/A | 7 | 0 up, 0 down | May 15, 2023 |
| Dec 31, 2022 | -$0.67 | -$0.29 | -$0.33 - -$0.26 | -131.03% | Miss | N/A | 7 | 0 up, 0 down | Mar 28, 2023 |
| Sep 30, 2022 | -$0.26 | -$0.28 | -$0.32 - -$0.23 | +7.14% | Beat | N/A | 7 | 0 up, 0 down | Nov 14, 2022 |
| Jun 30, 2022 | -$0.20 | -$0.28 | -$0.34 - -$0.15 | +28.57% | Beat | N/A | 6 | 0 up, 0 down | Aug 8, 2022 |
| Mar 31, 2022 | -$0.32 | -$0.22 | -$0.26 - -$0.18 | -45.45% | Miss | N/A | 5 | 0 up, 0 down | May 11, 2022 |
| Dec 31, 2021 | -$0.22 | -$0.24 | -$0.28 - -$0.18 | +8.33% | Beat | N/A | 6 | N/A | Mar 31, 2022 |
| Sep 30, 2021 | -$0.23 | -$0.20 | -$0.27 - -$0.17 | -15.00% | Miss | N/A | 6 | N/A | Nov 10, 2021 |
| Jun 30, 2021 | -$0.22 | -$0.16 | -$0.24 - -$0.12 | -37.50% | Miss | N/A | 7 | N/A | Aug 12, 2021 |
| Mar 31, 2021 | -$0.14 | -$0.17 | -$0.23 - -$0.17 | +17.65% | Beat | N/A | 4 | N/A | May 13, 2021 |
| Dec 31, 2020 | -$0.18 | -$0.19 | -$0.20 - -$0.18 | +5.26% | Beat | N/A | 3 | N/A | Mar 18, 2021 |
| Sep 30, 2020 | -$0.23 | -$0.14 | -$0.27 - -$0.14 | -64.29% | Miss | N/A | 2 | N/A | Nov 11, 2020 |
| Jun 30, 2020 | -$0.19 | -$0.23 | -$0.26 - -$0.20 | +17.39% | Beat | N/A | 2 | N/A | Aug 13, 2020 |
| Mar 31, 2020 | -$0.39 | -$0.15 | -$0.15 - -$0.15 | -160.00% | Miss | -126.5% | 1 | N/A | May 13, 2020 |
| Dec 31, 2019 | -$0.84 | -$0.92 | -$1.00 - -$0.85 | +8.70% | Beat | N/A | 2 | N/A | Mar 27, 2020 |
| Sep 30, 2019 | -$0.92 | -$0.82 | N/A | -12.20% | Miss | N/A | N/A | N/A | Nov 7, 2019 |
| Jun 30, 2019 | -$0.75 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 1, 2019 |
| Mar 31, 2019 | $1.47 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | May 14, 2019 |
| Dec 31, 2018 | -$0.10 | -$2.60 | N/A | +96.15% | Beat | N/A | N/A | N/A | Feb 21, 2019 |
| Sep 30, 2018 | -$2.29 | -$0.27 | N/A | -748.15% | Miss | N/A | N/A | N/A | Nov 1, 2018 |
| Jun 30, 2018 | -$8.20 | -$10.52 | N/A | +22.05% | Beat | N/A | N/A | N/A | Aug 1, 2018 |
| Mar 31, 2018 | -$13.40 | -$10.52 | N/A | -27.38% | Miss | N/A | N/A | N/A | May 1, 2018 |
| Dec 31, 2017 | -$9.00 | -$8.62 | N/A | -4.41% | Miss | N/A | N/A | N/A | Mar 1, 2018 |
| Sep 30, 2017 | -$7.40 | -$9.55 | N/A | +22.51% | Beat | N/A | N/A | N/A | Nov 1, 2017 |
| Jun 30, 2017 | -$8.80 | -$8.74 | N/A | -0.69% | Miss | N/A | N/A | N/A | Aug 1, 2017 |
| Mar 31, 2017 | -$8.40 | -$8.45 | N/A | +0.59% | Beat | N/A | N/A | N/A | May 3, 2017 |
| Dec 31, 2016 | -$6.60 | -$8.31 | N/A | +20.58% | Beat | N/A | N/A | N/A | Mar 2, 2017 |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$0.75, after -$1.03 the year before. It was -$27.00 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$0.75 | N/A |
| Dec 31, 2024 | -$1.03 | N/A |
| Dec 31, 2023 | -$1.39 | N/A |
| Dec 31, 2022 | -$1.45 | N/A |
| Dec 31, 2021 | -$0.81 | N/A |
| Dec 31, 2020 | -$0.99 | N/A |
| Dec 31, 2019 | -$1.04 | N/A |
| Dec 31, 2018 | -$23.99 | N/A |
| Dec 31, 2017 | -$33.60 | N/A |
| Dec 31, 2016 | -$27.00 | N/A |
Earnings Calls
The 6 most recent earnings calls are listed below; the latest, 2026Q1 for the period ended Mar 31, 2026, runs about 2,000 words across 7 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q1 | Mar 31, 2026 | 1,976 | 7 | |
| 2025Q4 | Dec 31, 2025 | 2,709 | 7 | |
| 2025Q3 | Sep 30, 2025 | 3,879 | 7 | |
| 2025Q2 | Jun 30, 2025 | 3,032 | 6 | |
| 2025Q1 | Mar 31, 2025 | 3,988 | 8 | |
| 2024Q3 | Sep 30, 2024 | 4,210 | 8 |
2026Q1 Earnings Call
Opening remarks
Dean Schwartz Host / Investor Relations Thank you, operator. Good morning, everyone, and welcome to PDS Biotech's First Quarter 2026 Results and Clinical Programs update call. I'm joined on the call today by the following members of the company's management team: Dr. Frank Bedu-Addo, Chief Executive Officer; Dr. Kirk Shepard, Chief Medical Officer; and Lars Boesgaard, Chief Financial Officer. Dr. Bedu-Addo and Dr. Shepard will provide an overview of the company's recent highlights in its clinical development program, and Mr. Boesgaard will review the financial results for the quarter ended March 31, 2026. Following management's prepared remarks, we will take questions from covering analysts. As a reminder, during this call, we will be making forward-looking statements, which are subject to various risks and uncertainties that could cause our actual results to differ materially from these statements. Any such statements should be considered in conjunction with cautionary statements in our press releases and risk factors discussed in our filings with the SEC, including our quarterly reports on Form 10-Q and annual report on Form 10-K and cautionary statements made during this call. We assume no obligation to update any of these forward-looking statements or information. Now I'd like to turn the call over to Dr. Bedu-Addo. Frank?
Frank Bedu-Addo Chief Executive Officer Thank you, Dean, and good morning, everyone. It's our pleasure to speak with you again and to provide this brief update on our progress in advancing our clinical programs. This past quarter, our major focus was on advancing our clinical programs and we made significant progress. So I will hand the call over to our Chief Medical Officer, Dr. Kirk Shepard, to provide an update. Kirk?
Kirk Shepard Chief Medical Officer Thank you, Frank. During our first quarter, we adopted an amendment to our VERSATILE-003 trial, revising the design to incorporate progression-free survival as an interim primary endpoint which we believe has the potential to enable a more efficient path to accelerated approval. We also believe this amendment may shorten the trial's duration and reduce the overall costs, all while retaining overall survival as a basis for full approval in accordance with FDA requirements. Additionally, this approach may also accelerate the availability of this promising treatment to the rapidly growing population of HPV16-positive patients in dire need of effective treatment. For patients living with HPV16-positive head and neck cancer, a disease with significant and growing unmet need, we believe PDS0101 represents a promising treatment option, and we remain focused on advancing it as efficiently as possible. PDS0101 in combination with KEYTRUDA (pembrolizumab) is the only late-stage investigational head and neck squamous cell carcinoma therapy that requires only 5 doses and is also the only subcutaneous therapy.
Frequently Asked Questions About PDSB
When is PDS Biotechnology's next earnings date?
PDS Biotechnology's next earnings report is expected for Mar 29, 2027.
Did PDSB beat earnings estimates last quarter?
No. PDS Biotechnology reported EPS of -$0.11 for the quarter ended Sep 30, 2026, below the -$0.09 estimate by 22.22%.
What EPS do analysts expect from PDSB next quarter?
The consensus EPS estimate for PDS Biotechnology for the quarter ending Dec 31, 2026 is -$0.09 from 4 analysts, with estimates from -$0.09 to -$0.09.
How often does PDSB beat earnings estimates?
PDS Biotechnology beat the EPS estimate in 6 of the last 8 quarters, with an average surprise of +2.57%.
PDSB pages: Overview, Earnings, Forecast, Financials, Competitors